ESSO 43 | Early clinical results from cellular therapies for melanoma
Andrew Furness, MD, PhD, Royal Marsden Hospital, London, UK, discusses the early results of off-the-shelf T-cell therapy for refractory melanoma, highlighting a response rate of around 30% and the potential for durable disease control among responders. He notes promising data from randomized studies, including one showing a 65% response rate when combining T-cell therapy with pembrolizumab in treatment-naive patients. While these findings are preliminary and based on small sample sizes, they indicate a significant step forward in managing melanoma. This interview took place at the ESSO 43 congress in Antwerp, Belgium.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
